Dr. Radhika Rachamalla

Hematology Oncology | Oncology | Hematology
45 Reade Pl, Fl 1, 
Poughkeepsie, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
45 Reade Pl, Fl 1, 
Poughkeepsie, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Radhika Rachamalla is a Hematologist Oncology specialist and an Oncologist in Poughkeepsie, New York. Dr. Rachamalla is rated as an Experienced provider by MediFind in the treatment of Glioblastoma. Her top areas of expertise are Paget Disease of the Breast, Lynch Syndrome, Colorectal Cancer, and Breast Cancer.

Her clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Putnam Hospital Center
Northern Dutchess Hospital
Vassar Brothers Medical Center
Sharon Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

NUVANCE HEALTH MEDICAL PRACTICE, PC
45 Reade Pl, Fl 1, Poughkeepsie, NY 12601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Distinguished in Glioblastoma
Dr. Deric M. Park
Neurology | Hematology | Oncology
Distinguished in Glioblastoma
Dr. Deric M. Park
Neurology | Hematology | Oncology

HMH - John Theurer Cancer Center - Hackensack

92 2nd Street, 
Hackensack, NJ 
 (56.1 miles away)
551-996-3033
Languages Spoken:
English
See accepted insurances

Deric Park is a Neurologist and a Hematologist in Hackensack, New Jersey. Dr. Park is rated as a Distinguished provider by MediFind in the treatment of Glioblastoma. His top areas of expertise are Gliosarcoma, Astrocytoma, Brain Tumor, and Glioblastoma.

Advanced in Glioblastoma
Dr. Daniel P. Petrylak
Oncology | Hematology Oncology
Advanced in Glioblastoma
Dr. Daniel P. Petrylak
Oncology | Hematology Oncology

Yale University

800 Howard Ave, 
New Haven, CT 
 (58.3 miles away)
203-785-2140
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Petrylak is an Oncologist and a Hematologist Oncology provider in New Haven, Connecticut. Dr. Petrylak is rated as an Elite provider by MediFind in the treatment of Glioblastoma. His top areas of expertise are Prostate Cancer, Urothelial Cancer, Familial Prostate Cancer, Orchiectomy, and Gamma Knife Radiosurgery.

Advanced in Glioblastoma
Dr. Courtney M. Bellomo
Hematology Oncology | Oncology | Hematology
Advanced in Glioblastoma
Dr. Courtney M. Bellomo
Hematology Oncology | Oncology | Hematology

New York Oncology Hematology PC

69 Prospect Ave, 
Hudson, NY 
 (38.9 miles away)
212-459-8173
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Courtney Bellomo is a Hematologist Oncology specialist and an Oncologist in Hudson, New York. Dr. Bellomo is rated as a Distinguished provider by MediFind in the treatment of Glioblastoma. Her top areas of expertise are Waldenstrom Macroglobulinemia, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rachamalla's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 24 Advanced Conditions
    View All 131 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile